Pfizer is to drop phase III development of two investigational compounds – esreboxetine for fibromyalgia and PD 332,334 for generalised anxiety disorder.
It says that it is “unlikely that either would provide meaningful benefit to patients beyond the current standard of care. Neither compound was terminated for safety reasons”.
Pedro Lichtinger, boss of Pfizer’s primary care business unit said: “We continually review our portfolio to ensure we are developing medicines in areas of unmet need, and have found significant potential opportunities to bring more value to patients and our company.
“For example, we are advancing the investigational compound tanezumab into areas of pain management beyond osteoarthritis, and see potential opportunities for other investigational compounds in other areas of significant patient need, including Alzheimer’s disease and thrombosis.”
He added: “Our goal is to use our resources efficiently and effectively to continue to deliver medical innovations to the global health community.”
Copyright Press Association 2009